InMode Ltd. (NASDAQ:INMD) Shares Sold by D.A. Davidson & CO.

D.A. Davidson & CO. cut its holdings in InMode Ltd. (NASDAQ:INMDFree Report) by 15.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,045 shares of the healthcare company’s stock after selling 5,344 shares during the quarter. D.A. Davidson & CO.’s holdings in InMode were worth $885,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Exchange Traded Concepts LLC acquired a new stake in shares of InMode during the third quarter valued at $27,000. Carmel Capital Partners LLC purchased a new stake in shares of InMode during the third quarter worth about $36,000. Newbridge Financial Services Group Inc. acquired a new position in shares of InMode in the third quarter valued at approximately $40,000. Brown Brothers Harriman & Co. purchased a new position in shares of InMode during the first quarter valued at approximately $41,000. Finally, Quarry LP lifted its stake in shares of InMode by 88.8% during the 1st quarter. Quarry LP now owns 1,601 shares of the healthcare company’s stock worth $51,000 after purchasing an additional 753 shares during the period. Hedge funds and other institutional investors own 65.49% of the company’s stock.

InMode Price Performance

NASDAQ INMD opened at $25.96 on Monday. InMode Ltd. has a 1-year low of $18.57 and a 1-year high of $48.25. The firm has a market capitalization of $2.15 billion, a P/E ratio of 12.36 and a beta of 2.22. The business’s 50-day simple moving average is $22.65 and its 200-day simple moving average is $27.68.

Wall Street Analyst Weigh In

INMD has been the subject of a number of recent analyst reports. TheStreet downgraded InMode from a “b-” rating to a “c+” rating in a research report on Thursday, October 19th. Canaccord Genuity Group restated a “hold” rating and issued a $22.00 price target on shares of InMode in a report on Thursday, December 7th. Barclays cut their price objective on shares of InMode from $33.00 to $32.00 and set an “overweight” rating on the stock in a report on Thursday, January 18th. Finally, UBS Group restated a “neutral” rating and issued a $24.00 target price (down from $52.00) on shares of InMode in a report on Friday, November 3rd. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, InMode presently has an average rating of “Hold” and an average target price of $36.83.

Check Out Our Latest Research Report on INMD

InMode Company Profile

(Free Report)

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.

Featured Articles

Want to see what other hedge funds are holding INMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InMode Ltd. (NASDAQ:INMDFree Report).

Institutional Ownership by Quarter for InMode (NASDAQ:INMD)

Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.